Volume 14 Issue 1
Jan.  2023
Turn off MathJax
Article Contents
CHEN Hongda, LIAO Xianzhen, DU Lingbin, DONG Dong, WEI Donghua, GAO Yi, ZHENG Weifang, CHEN Jingjun, LU Ming, ZHANG Yuhan, LU Bin, LUO Chenyu, LI Na, ZHOU Yueyang, LUO Jiahui, CAI Jie, SHI Jufang, DAI Min. Evaluation of the Effectiveness of Colonoscopy, Fecal Immunochemical Test and Risk-adapted Screening Strategies in Population-based Colorectal Cancer Screening: A Multicenter Randomized Controlled Trial[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 114-123. doi: 10.12290/xhyxzz.2022-0537
Citation: CHEN Hongda, LIAO Xianzhen, DU Lingbin, DONG Dong, WEI Donghua, GAO Yi, ZHENG Weifang, CHEN Jingjun, LU Ming, ZHANG Yuhan, LU Bin, LUO Chenyu, LI Na, ZHOU Yueyang, LUO Jiahui, CAI Jie, SHI Jufang, DAI Min. Evaluation of the Effectiveness of Colonoscopy, Fecal Immunochemical Test and Risk-adapted Screening Strategies in Population-based Colorectal Cancer Screening: A Multicenter Randomized Controlled Trial[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 114-123. doi: 10.12290/xhyxzz.2022-0537

Evaluation of the Effectiveness of Colonoscopy, Fecal Immunochemical Test and Risk-adapted Screening Strategies in Population-based Colorectal Cancer Screening: A Multicenter Randomized Controlled Trial

doi: 10.12290/xhyxzz.2022-0537
Funds:

National Natural Science Foundation of China 82173606

National Natural Science Foundation of China 82273726

Beijing Nova Program of Science and Technology Z191100001119065

Natural Science Foundation of Beijing Municipality 7202169

CAMS Innovation Fund for Medical Sciences 2017-I2M-1-006

CAMS Innovation Fund for Medical Sciences 2022-I2M-1-003

More Information
  • Corresponding author: DAI Min, E-mail: daimin2002@hotmail.com
  • Received Date: 2022-09-26
  • Accepted Date: 2022-11-22
  • Publish Date: 2023-01-30
  •   Objective  To evaluate the feasibility and effectiveness of colonoscopy, fecal immunochemical test(FIT) and risk-adapted screening strategies in population-based colorectal cancer screening.  Methods  Based on the randomized controlled trial of colorectal cancer screening(TARGET-C) which was carried out in 6 centers of 5 provinces in China from May 2018 to May 2021, the participants who met the inclusion criteria of the study were randomly assigned to one of the following screening intervention groups in a ratio of 1∶2∶2, which were colonoscopy group, FIT group and risk-adapted screening group(participants evaluated to be at high risk were recommended to undertake colonoscopy, those at low risk were recommended to undertake FIT and FIT positive people received colonoscopy). The 3 groups received different schemes of colorectal cancer screening, in which the colonoscopy group only received baseline screening, whereas the FIT group and the risk-adapted screening group received annual follow-up screening on the basis of baseline screening. The main outcome was the detection rate for advanced colorectal neoplasm(including colorectal cancer and advanced adenoma). The participation rate, detection rate for any neoplasm and resource load of colonoscopy among different screening groups were further analyzed.  Results  A total of 19 373 participants meeting the inclusion and exclusion criteria were enrolled, including 8082 males(41.7%) and 11 291 females(58.3%), with an average age of (60.5±6.5) years. Among them, 3883 were in the colonoscopy group, 7793 in the FIT group, and 7697 in the risk-adapted screening group. After 1 or 3 rounds of screening(2 rounds of follow-up screening completed in FIT group and risk-adapted screening group), the overall participation was the highest for the FIT group(99.3%), followed by the risk-adapted screening group(89.2%) and the coloscopy group(42.3%). According to the intention-to-treat analysis, the detection rates of advanced neoplasm in the colonoscopy group was higher than that in the FIT group(2.76% vs. 2.17%, ORcolonoscopy vs FIT=1.30, 95% CI: 1.01-1.65, P=0.037); there were no statistically significant differences regarding the detection rates of advanced neoplasm between the colonoscopy group and the risk-adapted screening group(2.76% vs. 2.35%, ORcolonoscopy vs risk-adapted screening=1.19, 95% CI: 0.93-1.51, P=0.156), and between the risk-adapted screening group and the FIT group(2.35% vs. 2.17%, ORrisk-adapted screening vs FIT=1.09, 95% CI: 0.88-1.34, P=0.440). The number of colonoscopies needed to be performed to detect one advanced neoplasm was used as an indicator to evaluate the resource load of colonoscopy. The number was the highest for the coloscopy group(15.4), followed by the risk-adapted screening group(10.2) and the FIT group(7.8).  Conclusions  The risk-adapted screening strategy is feasible and effective in population-based colorectal cancer screening, and could serve as an effective supplement to the traditional colonoscopy and FIT-based colorectal cancer screening strategies.
  • loading
  • [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi:  10.3322/caac.21660
    [2] Cardoso R, Guo F, Heisser T, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study[J]. Lancet Oncol, 2021, 22: 1002-1013. doi:  10.1016/S1470-2045(21)00199-6
    [3] Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70: 145-164. doi:  10.3322/caac.21601
    [4] Davidson KW, Barry MJ, Mangione CM, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement[J]. JAMA, 2021, 325: 1965-1977. doi:  10.1001/jama.2021.6238
    [5] Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society[J]. CA Cancer J Clin, 2018, 68: 250-281. doi:  10.3322/caac.21457
    [6] 国家癌症中心中国结直肠癌筛查与早诊早治指南制定专家组. 中国结直肠癌筛查与早诊早治指南(2020, 北京)[J]. 中华肿瘤杂志, 2021, 43: 16-38. doi:  10.3760/cma.j.cn112152-20210105-00010
    [7] Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer[J]. Lancet, 2019, 394: 1467-1480. doi:  10.1016/S0140-6736(19)32319-0
    [8] Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know[J]. Gut, 2015, 64: 1327-1337. doi:  10.1136/gutjnl-2014-308074
    [9] Peng L, Balavarca Y, Weigl K, et al. Head-to-Head Comparison of the Performance of 17 Risk Models for Predicting Presence of Advanced Neoplasms in Colorectal Cancer Screening[J]. Am J Gastroenterol, 2019, 114: 1520-1530. doi:  10.14309/ajg.0000000000000370
    [10] Chen H, Li N, Shi J, et al. Comparative evaluation of novel screening strategies for colorectal cancer screening in China(TARGET-C): a study protocol for a multicentre randomised controlled trial[J]. BMJ Open, 2019, 9: e025935. doi:  10.1136/bmjopen-2018-025935
    [11] Lu M, Zhang Y, Cai J, et al. Head-to-head comparison of a risk-adapted screening strategy using various risk prediction models in detecting colorectal neoplasm[J]. J Gastroenterol Hepatol, 2022, 37: 1244-1252. doi:  10.1111/jgh.15825
    [12] Sung JJY, Wong MCS, Lam TYT, et al. A modified colorectal screening score for prediction of advanced neoplasia: A prospective study of 5744 subjects[J]. J Gastroenterol Hepatol, 2018, 33: 187-194.
    [13] Chen H, Li N, Ren J, et al. Participation and yield of a population-based colorectal cancer screening programme in China[J]. Gut, 2019, 68: 1450-1457. doi:  10.1136/gutjnl-2018-317124
    [14] Chiu HM, Ching JY, Wu KC, et al. A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms[J]. Gastroenterology, 2016, 150: 617-625. e3. doi:  10.1053/j.gastro.2015.11.042
    [15] Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multi-target stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 370: 1287-1297. doi:  10.1056/NEJMoa1311194
    [16] Bretthauer M, Kaminski MF, Løberg M, et al. Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial[J]. JAMA Intern Med, 2016, 176: 894-902. doi:  10.1001/jamainternmed.2016.0960
    [17] 王宝权, 柴晓银, 蓝柳豪, 等. 2018-2019年浙江省兰溪市结直肠癌筛查项目成本-效果分析[J]. 中国肿瘤, 2020, 29: 914-918. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU202012005.htm
    [18] 陈宏达, 卢明, 刘成成, 等. 结肠镜、免疫法粪便隐血试验和新型风险评估筛查方案在人群结直肠癌筛查中的参与率比较及其影响因素分析[J]. 中华流行病学杂志, 2020, 41: 1655-1661.
    [19] 王乐, 李辉章, 朱陈, 等. 浙江省2013-2018年城市居民结直肠癌筛查结果及成本效果分析[J]. 中华流行病学杂志, 2020, 41: 2080-2086. doi:  10.3760/cma.j.cn112338-20200324-00424
    [20] Chen H, Lu M, Liu C, et al. Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial(TARGET-C)[J]. Am J Gastroenterol, 2020, 115: 1264-1274. doi:  10.14309/ajg.0000000000000624
    [21] Chen X, Li H, Guo F, et al. Alcohol consumption, polygenic risk score, and early-and late-onset colorectal cancer risk[J]. EClinicalMedicine, 2022, 49: 101460.
    [22] Ping J, Yang Y, Wen W, et al. Developing and validating polygenic risk scores for colorectal cancer risk prediction in East Asians[J]. Int J Cancer, 2022, 151: 1726-1736.
    [23] Chen H, Liu L, Lu M, et al. Implications of Lifestyle Factors and Polygenic Risk Score for Absolute Risk Prediction of Colorectal Neoplasm and Risk-Adapted Screening[J]. Front Mol Biosci, 2021, 8: 685410.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Article Metrics

    Article views (2909) PDF downloads(123) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return